TiGenix Starts Global Phase 3 Trial to Evaluate Cx601 as a Treatment for Crohn’s Fistulas

TiGenix Starts Global Phase 3 Trial to Evaluate Cx601 as a Treatment for Crohn’s Fistulas
TiGenix has started a pivotal Phase 3 clinical trial of Cx601’s ability to treat a complication of Crohn’s disease known as complex perianal fistulas. Fistulas are sores between the end of the bowel and the skin near the anus. Cx601 uses stem cells to treat them after other therapies have failed. Fistulas can cause bleeding and discharge when defecating, and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

3 comments

  1. William Bottorf says:

    This would be a life saver. I just hope that the cost isn’t outrageous and it is available soon because I just can’t seem to get rid of them. Been 7 years and counting…
    Thank you for researching and trying to help people with this shitty (pun intended) problem.

  2. paulios says:

    I’m another one. One of the unlucky crohn’s victims if you will. 12 fistulas before I had colostomy. Then they return in the muscle and flesh and recent count is 4.
    Almost 20 years of these.
    I love to read such news. IBD research is gaining traction and heading towards the goal. . Hopefully we get there before I’m gone, but if not it will help so many in the future.

Leave a Comment

Your email address will not be published. Required fields are marked *